Opinion|Videos|June 25, 2024
Non-adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.
Advertisement
Episodes in this series
- The
RENOIR trial studied the safety and efficacy of non-adjuvanted vaccine in adults aged 60 years or older. What interim results were significant from this trial leading to the indication of the vaccine for this population?- Efficacy at preventing RSV-associated lower respiratory tract infections
- Adverse effects
- Trial limitations
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
2
FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery
3
Advancing the Role of Pharmacy Technicians in Hazardous Drug Compounding
4
How Pharmacists Can Close the Opioid Addiction Care Gap
5